This site is intended for healthcare professionals
Journals
  • Home
  • /
  • Journals
  • /
  • Ovarian Cancer
  • /
  • Targeting tumor microenvironment in ovarian cancer...
Journal

Targeting tumor microenvironment in ovarian cancer: Premise and promise

Read time: 1 mins
Published:1st Apr 2020
Author: Jiang Y, Wang C, Zhou S.
Availability: Pay for access, or by subscription
Ref.:Biochim Biophys Acta Rev Cancer. 2020 Apr;1873(2):188361.
DOI:10.1016/j.bbcan.2020.188361
Targeting tumor microenvironment in ovarian cancer: Premise and promise


Ovarian cancer is the leading cause of gynecological cancer-related mortality globally. The majority of ovarian cancer patients suffer from relapse after standard of care therapies and the clinical benefits from cancer therapies are not satisfactory owing to drug resistance. Certain novel drugs targeting the components of tumor microenvironment (TME) have been approved by US Food and Drug Administration in solid cancers. As such, the passion is rekindled to exploit the role of TME in ovarian cancer progression and metastasis for discovery of novel therapeutics for this deadly disease. In the current review, we revisit the recent mechanistic insights into the contributions of TME to the development, progression, prognosis prediction and therapeutic efficacy of ovarian cancer via modulating cancer hallmarks. We also explored potentially promising predictive and prognostic biomarkers for ovarian cancer patients.


Read abstract on library site Access full article